Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report which forecasts that Pfizer’s Chantix™ (varenicline) could revolutionise the current addiction treatment market.
Smoking Cessation and Addiction Treatments - A World Market Analysis says that Chantix, approved by the FDA in 2006, together with the fact that there are greater reimbursement levels for addiction treatments, can propel global sales of smoking cessation and other addition treatments to over $2.3 billion in 2010.
There are approximately 1.4 billion smokers in the world, 50 million of them located in the U.S . Smoking is a known cause of heart, lung and other respiratory diseases and the sheer number of smokers makes nicotine one of the most abused substances across the world. Campaigns to stop smoking are high on the agenda of global health agencies as well as governments. This ensures that there is an increasing awareness of the dangers of nicotine, and also of the availability of effective smoking cessation products. This means that any new smoking cessation drug making anentrance has a strong market potential for robust growth.
The largest share of the market is currently cornered by GlaxoSmithKline with Zyban smoking cessation treatment and Shering Plough / Reckitt Benckiser with the Suboxone/Subetex substance abuse treatment. Analysts predict that Pfizer entering the smoking cessation segment with Chantix is likely to tip the scales.
Authors of the report believe that Chantix from Pfizer (known in Europe as Champix) could edge out GlaxoSmithKline, and all other competitors in smoking cessation to dominate the market due to its superior effectiveness in the clinical trial stage. They also suggest that on a more modest scale, other new drugs in alcohol and substance abuse treatments will contribute to changing the present market order.
The report contains world incidence data for nicotine addiction, drug addiction and alcohol abuse. It also has a round up of current products available, as well as a review of products in the pipeline. The study outlines key trends driving pharmaceutical treatments for smoking cessation and drug/alcohol addiction, and breaks down the market share occupied by major players and brands.
Report Buyer product ID: KAL00013
